Want to see STOK full AI Analyst Report?
STOK Stock Chart & Stats
$29.30
$0.81(2.76%)
At close: 4:00 PM EDT
$29.30
$0.81(2.76%)
Day’s Range― - ―
52-Week Range$12.25 - $40.22
Previous CloseN/A
Volume36.19K
Average Volume (3M)885.20K
Market Cap
$1.83B
Enterprise Value$1.71K
Total Cash (Recent Filing)$343.55M
Total Debt (Recent Filing)$3.42M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 03, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding62,281,654
10 Day Avg. Volume538,018
30 Day Avg. Volume885,195
Financial Highlights & Ratios
PEG Ratio2.85
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$47.38Price Target Upside61.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.33
Revenue Forecast (FY)$25.72M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetNear-zero debt gives Stoke durable financial flexibility to fund clinical programs and negotiate partnerships without immediate refinancing pressure. Low leverage reduces insolvency risk, supports R&D spending cadence, and preserves strategic optionality through the 2-6 month regulatory and enrollment milestones cycle.
Phase 3 Enrollment Complete; Regulatory PathCompleting primary enrollment materially lowers execution risk and enables a defined regulatory timetable (rolling NDA Q1 2027, readout expected Q3 2027). This structural progress strengthens the likelihood of data-driven milestones, potential partner interest, and non-dilutive milestone payments if outcomes support approval.
High Gross Profitability When Revenue ExistsConsistently strong gross margins indicate favorable product economics for ASO therapies and scalable manufacturing leverage. If Stoke achieves approvals, high gross profitability can translate into durable operating leverage and attractive incremental margins as commercial volumes grow and fixed R&D/SG&A are absorbed.
Bears Say
Elevated Cash BurnSustained large negative operating and free cash flow implies material reliance on external financing or partnerships to advance trials. High burn over multiple quarters can force dilutive capital raises, constrain strategic choices, and shorten runway if clinical timelines extend, pressuring long-term capital structure.
Sharp Revenue Decline And Deep LossesAn abrupt revenue drop and extreme negative margins reflect volatile, loss-making operations and limited recurring commercial sales. This weak operational cash generation undermines internal funding capacity, increases dependence on milestone or partner receipts, and raises execution risk across development programs.
Binary Clinical And Timing RiskStoke's value and ability to monetize hinge on Phase 3 outcome and subsequent regulatory review—binary events with long timelines. Negative or delayed results would materially impair commercialization prospects, partnership economics, and the company's financial runway, a persistent structural risk for clinical-stage biotech.
Stoke Therapeutics News
STOK FAQ
What was Stoke Therapeutics’s price range in the past 12 months?
Stoke Therapeutics lowest stock price was $12.25 and its highest was $40.22 in the past 12 months.
What is Stoke Therapeutics’s market cap?
Stoke Therapeutics’s market cap is $1.83B.
When is Stoke Therapeutics’s upcoming earnings report date?
Stoke Therapeutics’s upcoming earnings report date is Aug 03, 2026 which is in 4 days.
How were Stoke Therapeutics’s earnings last quarter?
Stoke Therapeutics released its earnings results on May 07, 2026. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$0.808 by $0.018.
Is Stoke Therapeutics overvalued?
According to Wall Street analysts Stoke Therapeutics’s price is currently Undervalued.
Does Stoke Therapeutics pay dividends?
Stoke Therapeutics does not currently pay dividends.
What is Stoke Therapeutics’s EPS estimate?
Stoke Therapeutics’s EPS estimate is -0.8.
How many shares outstanding does Stoke Therapeutics have?
Stoke Therapeutics has 62,281,654 shares outstanding.
What happened to Stoke Therapeutics’s price movement after its last earnings report?
Stoke Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$0.808. Following the earnings report the stock price went up 0.305%.
Which hedge fund is a major shareholder of Stoke Therapeutics?
Currently, no hedge funds are holding shares in STOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.38 (61.69% Upside)
$47.38 (61.69% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 67%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 41.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
116.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.94%
Trailing 12-Months
Company Description
Stoke Therapeutics
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
STOK Company Deck
STOK Earnings Call
Q1 2026
0:00 / 0:00
STOK Stock 12 Month Forecast
Average Price Target
$47.38
▲(61.69% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Xeris Pharmaceuticals
―
―
Rapport Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
28.38% Insiders
20.88% Mutual Funds
2.62% Other Institutional Investors
32.55% Public Companies and
Individual Investors